Deciphera Pharmaceuticals
Waltham
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $1.0B
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2023)
- Ticker: nasdaq:DCPH
- Website: deciphera.com
- Phone: (781) 209-6400
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/deciphera-pharmaceuticals-66144 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.